Cytotoxin T lymphocyte
Patent Information
- Authority / Receiving Office
- CN · China
- Current Assignee / Owner
- TAKARA HOLDINGS
- Publication Date
- 2002-11-13
- Estimated Expiration
- Not applicable · inactive patent
Smart Images
Figure 1 Figure 2
Abstract
Description
technical field
[0001] The present invention relates to a technique useful in the treatment and diagnosis of diseases caused by abnormal expression of prostate specific membrane antigen (prostate specific membrane antigen, hereinafter abbreviated as PSMA), such as cancer, and specifically, prostate cancer. More specifically, the present invention relates to a compound having a recognizable antigenic peptide and a human major histocompatibility antigen (HLA) molecule useful in the treatment and diagnosis of cancer, specifically prostate cancer and other cancers with abnormal expression of PMSA. Cytotoxic T lymphocytes (cytotoxic T lymphocytes, hereinafter abbreviated as CTL) of the T cell receptor, the antigenic peptide, a CTL inducer useful for inducing the CTL, etc., a method for inducing the CTL, and an anticancer drug useful for the above-mentioned cancer , the detection method of the CTL sensitive cell and its detection reagent, the detection method of the HLA-A24 molecule...